Curis, Inc. (CRIS)
Curis, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Curis, Inc. (CRIS) is a Biotechnology company based in US with a market capitalization of $9.3M. Revenue declined 13.4% year-over-year and free cash flow was negative at -$27.2M. This page tracks CRIS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 34 employees · IPO Aug 1, 2000
Valuation
Valuation & price
$0.49as of May 17, 2026· -98.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.69
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$9.3M
Market cap
-13.4%
Revenue growth (YoY)
99.5%
Gross margin
-$27.2M
Free cash flow (USD)
-$3.4M
Net debt
Net cash position
1987.5%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 2, 2026Filing
Reverse Stock Split
- 8-K eventJul 1, 2026Filing
Reverse Stock Split
- 8-K eventJul 1, 2026Filing
Reverse Stock Split
- 8-K eventJun 25, 2026Filing
Stockholder Meeting Results
- 8-K eventMay 22, 2026Filing
Share Authorization Increase
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- 8-K eventMay 12, 2026Filing
Earnings Release
- 8-K eventMay 1, 2026Filing
Delisting Notice
- Insider buyApr 1, 2026Filing
Insider Buy $5KKAITIN KENNETH I · Director · $5.5K
Questions
Frequently asked questions
What is Curis, Inc.'s market cap?
Curis, Inc. (CRIS) has a market capitalization of $9.3M.
What is CRIS's P/E ratio?
A meaningful P/E ratio is not available for CRIS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CRIS's price-to-book (P/B) ratio?
CRIS trades at 1.69 times book value per share.
Are insiders buying CRIS stock?
SEC Form 4 filings show no open-market insider buys at Curis, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.